Mark Sheptoff Financial Planning LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 19.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,415 shares of the pharmaceutical company’s stock after buying an additional 1,825 shares during the quarter. Vertex Pharmaceuticals comprises about 1.2% of Mark Sheptoff Financial Planning LLC’s investment portfolio, making the stock its 24th biggest position. Mark Sheptoff Financial Planning LLC’s holdings in Vertex Pharmaceuticals were worth $1,736,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jennison Associates LLC increased its holdings in Vertex Pharmaceuticals by 253.8% in the 2nd quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock valued at $651,454,000 after purchasing an additional 3,626,368 shares in the last quarter. Old Mutual Global Investors UK Ltd. increased its holdings in Vertex Pharmaceuticals by 1,384.7% in the 2nd quarter. Old Mutual Global Investors UK Ltd. now owns 1,195,455 shares of the pharmaceutical company’s stock valued at $154,058,000 after purchasing an additional 1,114,939 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Vertex Pharmaceuticals by 9,422.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after purchasing an additional 883,998 shares in the last quarter. AJO LP acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $71,956,000. Finally, Vanguard Group Inc. increased its holdings in Vertex Pharmaceuticals by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after purchasing an additional 504,982 shares in the last quarter. 92.42% of the stock is currently owned by institutional investors and hedge funds.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 221 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $147.29, for a total value of $32,551.09. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP David Altshuler sold 1,796 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $160.00, for a total transaction of $287,360.00. Following the completion of the transaction, the executive vice president now directly owns 107,807 shares in the company, valued at approximately $17,249,120. The disclosure for this sale can be found here. Insiders sold 220,315 shares of company stock valued at $32,107,270 over the last quarter. Insiders own 1.80% of the company’s stock.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $147.04 on Friday. The company has a market capitalization of $37,186.83, a PE ratio of 245.07, a P/E/G ratio of 3.74 and a beta of 1.63. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The company’s revenue for the quarter was up 39.7% compared to the same quarter last year. During the same period last year, the firm earned $0.16 earnings per share. analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current fiscal year.

VRTX has been the subject of several recent research reports. Cowen Inc reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. Zacks Investment Research downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. DA Davidson initiated coverage on Vertex Pharmaceuticals in a research note on Friday, September 29th. They set a “buy” rating and a $200.00 target price for the company. Jefferies Group LLC restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 22nd. Finally, Maxim Group set a $195.00 target price on Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have given a buy rating to the stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $173.15.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/mark-sheptoff-financial-planning-llc-raises-position-in-vertex-pharmaceuticals-incorporated-vrtx/1723601.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.